SCHEMBL4501693

SCHEMBL4501693

C=CCOc1ccc(C=O)c(C)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.54
HPGD P15428 3/20 0.54
GAA P10253 2/20 0.54
CA12 O43570 5/20 0.44
CA1 P00915 5/20 0.44
CA9 Q16790 5/20 0.44
MAPT P10636 2/20 0.44
LMNA P02545 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
NPSR1 Q6W5P4 1/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
CA2 P00918 1/20 0.42
CA7 P43166 1/20 0.42
ADRA2A P08913 1/20 0.42
ADRA2B P18089 1/20 0.42
ADRA2C P18825 1/20 0.42
MAOA P21397 1/20 0.41
FGFR1 P11362 1/20 0.40
AGER Q15109 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28517850 0.86 ALDH1A1 (0.49) ALDH1A1HPGDGAACA12CA1
SCHEMBL7796875 0.84 ALDH1A1 (0.42) ALDH1A1HPGDGAACA12CA1
SCHEMBL22322049 0.83 ALDH1A1 (0.41) ALDH1A1HPGDGAAMAPTSMN1; SMN2
SCHEMBL1520406 0.81 ALDH1A1 (0.47) ALDH1A1HPGDGAACA12CA1
SCHEMBL3721962 0.81 ALDH1A1 (0.47) ALDH1A1HPGDGAACA12CA1
SCHEMBL27762926 0.80 ALDH1A1 (0.53) ALDH1A1HPGDGAACA12CA1
SCHEMBL6931077 0.80 CA12 (0.44) ALDH1A1HPGDGAACA12CA1
SCHEMBL28011522 0.80 CA12 (0.46) ALDH1A1HPGDGAACA12CA1
SCHEMBL7046014 0.80 TDP1 (0.47) ALDH1A1HPGDGAACA12CA1
SCHEMBL6561561 0.80 TRIM24 (0.57) ALDH1A1HPGDGAACA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090264485-A1 Pyrazole Derivatives, Their Manufacture and Their Use as Pharmaceutical Agents F. HOFFMANN-LA ROCHE AG (CH) 2009-10-22 US disclosed
US-20090264485-A1 Pyrazole Derivatives, Their Manufacture and Their Use as Pharmaceutical Agents F. HOFFMANN-LA ROCHE AG (CH) 2009-10-22 US disclosed
US-20090264485-A1 Pyrazole Derivatives, Their Manufacture and Their Use as Pharmaceutical Agents F. HOFFMANN-LA ROCHE AG (CH) 2009-10-22 US disclosed
US-7432291-B2 Ether derivatives HOFFMAN-LA ROCHE INC. (US) 2008-10-07 US disclosed
EP-1761525-B1 THIOETHER DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS HOFFMANN LA ROCHE (CH) 2008-07-23 EP disclosed
CN-101208335-A Pyrazole derivatives, their manufacture and their use as pharmaceutical agents HOFFMANN LA ROCHE (CH) 2008-06-25 CN disclosed
EP-1915370-A1 PYRAZOLE DERIVATIVES, THEIR MANUFACTURE AND THEIR USE AS PHARMACEUTICAL AGENTS F.HOFFMANN-LA ROCHE AG (CH) 2008-04-30 EP disclosed
EP-1727815-B1 ETHER DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS HOFFMANN LA ROCHE (CH) 2007-06-27 EP disclosed
CN-1950366-A Thioether derivatives, their preparation and use as pharmaceutical agents HOFFMANN LA ROCHE (CH) 2007-04-18 CN disclosed
CN-1930154-A Ether derivatives, their manufacture and use as pharmaceutical agents HOFFMANN LA ROCHE (CH) 2007-03-14 CN disclosed
US-5952360-A Method for treating neuropathic pain ELI LILLY AND COMPANY (US) 1999-09-14 US disclosed
US-5942530-A Method for treating pain ELI LILLY AND COMPANY (US) 1999-08-24 US disclosed
WO-1999018091-A1 NOVEL COMPOUNDS USEFUL AS NEURO-PROTECTIVE AGENTS ELI LILLY AND COMPANY (US) 1999-04-15 WO disclosed
EP-0908186-A2 Method for treating pain ELI LILLY AND COMPANY (US) 1999-04-14 EP disclosed
EP-0908454-A2 Oxazoles, thiazoles, oxazolines, oxadiazoles and benzoxazoles useful as neuro-protective agents ELI LILLY AND COMPANY (US) 1999-04-14 EP disclosed
EP-0908180-A2 Use of phenyl oxazole or phenyl thiazole derivatives for treating pain ELI LILLY AND COMPANY (US) 1999-04-14 EP disclosed
WO-1999009829-A1 METHOD FOR TREATING PAIN ELI LILLY AND COMPANY (US) 1999-03-04 WO disclosed
WO-1999009979-A1 METHOD FOR TREATING NEUROPATHIC PAIN ELI LILLY AND COMPANY (US) 1999-03-04 WO disclosed
WO-1999009980-A1 METHOD FOR TREATING PAIN ELI LILLY AND COMPANY (US) 1999-03-04 WO disclosed
WO-1998015274-A1 NOVEL COMPOUNDS USEFUL AS NEURO-PROTECTIVE AGENTS ELI LILLY AND COMPANY (US) 1998-04-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264485-A1 Pyrazole Derivatives, Their Manufacture and Their Use as Pharmaceutical Agents CYP3A5, CYP3A43, CYP3A7 ALDH1A1 128/4885HPGD 138/4885GAA 1984/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.